Mark Meadowcroft, Ph.D
Dr. Mark Meadowcroft’s research focus revolves around the translational usage of in vivo and ex vivo imaging of clinical and preclinical transgenic animal models to study and develop potential treatments and/or biomarkers of neurological diseases and conditions.
His laboratory is currently undertaking clinical and preclinical studies involving murine (mouse and rat) and lagomorph (rabbit) animal models as well as post-mortem imaging in the study of normal aging, Alzheimer’s disease, Parkinson’s disease, ALS and neurovascular processes. Their multi-model approach tailors the usage of quantitative MRI relaxometry, diffusion, contrast-enhanced and functional metrics paired with genetic, biochemical, histological and molecular technologies to aid in understanding the neurodegenerative disease process to develop biomarker and treatment strategies.
Dr. Meadowcroft's expertise leverages application of translational neuroimaging techniques coupled with an understanding of the histo-pathological basis of magnetic resonance imaging metrics and genomics and their association to various neurological and neurodegenerative processes. Magnetic resonance imaging has emerged as a powerful tool for soft-tissue imaging of static and time-sensitive biological events in real time, allowing the exploration of novel medical techniques. The aim is to further enhance our understanding of genomics and molecular/biological interactions in neurodegenerative processes and move forward testing and validation of innovative therapeutic strategies. Through this approach, a relationship between MR imaging parametrics, molecular processes, genetics and biochemical histological standards can be ascribed to disease state.